Mutual Fund Details
NAV
₹468.6636
as on 19 Nov 2024, 09:00 PM
₹3.8719(0.83%)
Last Change
Scheme Ratings
4
Pharma
5Y Returns
4
rated by Value Research
Pharma
Rankings based on 5Y Returns | as on 18 Nov 2024
×
1
DSP Healthcare Fund Direct - Growth
32.64%
2
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
31.24%
3
Mirae Asset Healthcare Fund Direct - Growth
30.20%
4
SBI Healthcare Opportunities Fund Direct Plan-Growth
30.00%
5
UTI Healthcare Fund Direct-Growth
28.75%
Investment Performance
would have given a return of
₹1,10,871
₹1,21,647
₹1,85,862
₹1,91,917
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
₹91,917
Profit (absolute return)
91.92%
in the last
1m
3m
1y
3y
5y
max
+1% Higher Returns
With Direct Plans on Paytm MoneyInvestment Returns
In the last 3 months
5.16%
In the last 6 months
19.20%
In the last 1 year
44.71%
In the last 3 years
91.92%
In the last 5 years
271.83%
In the last 10 years
294.38%
Absolute Returns
CAGR
Scheme Riskometer
low
low to moderate
moderate
moderately high
high
very high
Investors understand that their principal will be at very high risk
Scheme Information
SBI Healthcare Opportunities Fund Direct Plan-Growth
as of 31 Oct 2024, 05:30 AM
₹3,416.13 Cr
Scheme Asset Size
Fund Type
Open-End
Exit Load
Exit load of 0.50% if redeemed within 15 days
0.89%
Expense Ratio
Plan
Growth
Benchmark
BSE Healthcare Total Return Index
Exit Load
Exit load of 0.50% if redeemed within 15 days
Scheme Document
Sectors Holding in this Mutual Fund
as on 31 Oct 2024
Healthcare
93.23%
₹3,184.86 Cr
Chemicals
3.50%
₹119.56 Cr
Others
3.27%
₹111.71 Cr
Companies Holding in this Mutual Fund
as on 31 Oct 2024
Sun Pharmaceutical Industries Ltd.
13.78%
₹470.74 Cr
Max Healthcare Institute Ltd.
7.67%
₹262.02 Cr
Divi's Laboratories Ltd.
6.66%
₹227.51 Cr
Cipla Ltd.
6.65%
₹227.17 Cr
Lonza Group Ag
4.94%
₹168.76 Cr
Others
60.30%
₹2,059.93 Cr
View All
View All
Companies Holding in this Mutual Fund
as on 31 Oct 2024
Sun Pharmaceutical Industries Ltd.
13.78%
₹470.74 Cr
Max Healthcare Institute Ltd.
7.67%
₹262.02 Cr
Divi's Laboratories Ltd.
6.66%
₹227.51 Cr
Cipla Ltd.
6.65%
₹227.17 Cr
Lonza Group Ag
4.94%
₹168.76 Cr
Others
60.30%
₹2,059.93 Cr
View All
View All
This fund's returns:
24.22%Return Duration
3 Years
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
15.16%
24.24%
3Y Returns
24.24
DSP Healthcare Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
15.16%
24.24%
3Y Returns
22.89
Tata India Pharma & HealthCare Fund Direct-Growth
EquityPharma
Min. Investment
₹100
Category Returns
15.16%
24.24%
3Y Returns
20.99
About SBI Healthcare Opportunities Fund Direct Plan-Growth
SBI Healthcare Opportunities Fund Direct Plan-Growth is a Equity mutual fund scheme from SBI Mutual Fund. This scheme was launched on Invalid date. It has an AUM of ₹3,416.13 Crores and the latest NAV decalared is ₹468.664 as on 21 Nov 2024 at 9:20 pm.
SBI Healthcare Opportunities Fund Direct Plan-Growth scheme return performance in last 1 year is 44.71%, in last 3 years is 91.92% and 678.51% since scheme launch. The min. SIP amount to invest in this scheme is ₹500.
Scheme Details
| AUM: | ₹3,416.13 Cr |
| Category: | Equity: Sectoral-Pharma |
| Launch Date: | Invalid date |
| Fund Type: | Open-End |
AMC Information
SBI Mutual Fund
View AMC Details
₹11,03,644.19 Cr
AUM
168
Schemes
Address
9th Floor-Crescenzo, C-38 & 39-G Block, Bandra-Kurla Complex,Bandra (East)400051
Phone Number
Phone : 022-61793000 / 1800-425-5425
Fax : 022-22189663
Email / Website
Start investing in minutes
Download app to Explore
Scan this QR code to download the app now!
Or download from
